Amyris Inc (NASDAQ:AMRS) saw some unusual options trading on Wednesday. Stock investors purchased 813 call options on the stock. This represents an increase of approximately 1,406% compared to the typical daily volume of 54 call options.
Several institutional investors and hedge funds have recently modified their holdings of AMRS. Tanaka Capital Management Inc. increased its stake in shares of Amyris by 72.0% in the 3rd quarter. Tanaka Capital Management Inc. now owns 528,549 shares of the biotechnology company’s stock valued at $1,691,000 after purchasing an additional 221,295 shares during the last quarter. Carl Domino Inc bought a new stake in Amyris during the 3rd quarter worth $182,000. KBC Group NV grew its position in Amyris by 228.4% during the 3rd quarter. KBC Group NV now owns 60,154 shares of the biotechnology company’s stock worth $192,000 after acquiring an additional 41,834 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its position in Amyris by 16.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 32,768 shares of the biotechnology company’s stock worth $104,000 after acquiring an additional 4,603 shares during the last quarter. Institutional investors own 22.84% of the company’s stock.
Several brokerages have recently issued reports on AMRS. ValuEngine lowered Amyris from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. HC Wainwright set a $15.00 price target on Amyris and gave the company a “buy” rating in a research note on Wednesday, November 29th. Cowen reiterated a “hold” rating and issued a $4.00 price target on shares of Amyris in a research note on Wednesday, November 29th. Finally, Zacks Investment Research lowered Amyris from a “buy” rating to a “hold” rating in a research note on Monday, October 23rd.
Amyris (NASDAQ:AMRS) opened at $4.64 on Friday. Amyris has a 52 week low of $1.86 and a 52 week high of $12.28. The company has a quick ratio of 0.82, a current ratio of 0.92 and a debt-to-equity ratio of -0.78. The stock has a market capitalization of $199.68, a price-to-earnings ratio of -0.75 and a beta of 0.16.
Amyris (NASDAQ:AMRS) last issued its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.81) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by ($0.04). The firm had revenue of $24.20 million during the quarter, compared to the consensus estimate of $36.30 million. During the same quarter last year, the firm posted ($0.07) EPS. The business’s revenue was down 8.8% on a year-over-year basis. sell-side analysts expect that Amyris will post -3.32 earnings per share for the current year.
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.